Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
暂无分享，去创建一个
R. Pieters | V. V. D. van der Velden | M. Schrappe | A. Attarbaschi | J. Zuna | J. Starý | J. Boer | A. Vora | T. Szczepański | A. Biondi | G. Cazzaniga | J. Stutterheim | B. Lausen | P. de Lorenzo | R. Kotecha | A. Ferster | B. Brethon | M. Valsecchi | J. Alten | A. Leung | L. Aversa | F. Locatelli | P. Ancliffe | G. Escherich | P. Diaz | L. Silverman | I.M. van der Sluin